The widespread introduction of saphenous vein grafting to bypass atheromatous lesions of the coronary arteries over 15 years ago' has had a profound effect on the management of ischaemic heart disease. It has been estimated that 65 000 such procedures were carried out in the United States of America during 1975,2 and the annual rate has probably risen appreciably during the subsequent decade. The benefits of coronary artery bypass grafting have been the subject of much debate, but there is now increasing evidence that this procedure not only relieves symptoms but also increases longevity.3
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Need for grafting in hyperlipidaemic patients
Numerous studies have shown a relation between the severity of angiographically assessed coronary artery disease and hyperlipidaemia,4'4 as judged by the age of onset of symptoms,47 the multiplicity of vessels involved,5 7 and the tendency for lesions to progress.6 10 ing out this procedure will occur relatively more often in hypercholesterolaemic patients than in those with normal serum lipid concentrations. In individuals with the rare homozygous form of familial hypercholesterolaemia bypass grafts are performed prophylactically to minimise the hazards of the ostial stenosis to which they are so prone or as an accompaniment to the formidable procedure which involves excision of the atheromatous aortic valve, enlargement of the aortic annulus, and insertion of a BjorkShiley prosthesis. '9 Effect of hyperlipidaemia on saphenous vein grafts An early study20 suggested that grafts patent at two weeks occluded more frequently during the subsequent year in patients whose serum triglyceride concentrations were raised preoperatively or postoperatively than in those with normal values. This was attributed to the fact that hypertriglyceridaemia tends to be associated with hypercoagulability, as was confirmed recently,2' thus predisposing to early thrombotic occlusion. Histological studies of grafts obtained at the time of reoperation or necropsy several years after the initial procedure showed atheromatous changes which were largely confined to individuals who remained hyperlipidaemic postoperatively.22 23 A similar but larger study showed a five fold increase in the incidence of vein graft atheroma in hyperlipidaemic compared with normolipidaemic individuals dying 1-5 years after coronary artery bypass grafting. 24 Recently, three angiographic studies with varying periods of follow up have been reported. The largest but shortest study found that the majority of grafts patent at one year were unchanged three years after operation.25 Progression of disease in grafts was evident in only 11% of 221 patients and was unrelated to serum cholesterol concentration. Nevertheless, a longer study showed progressive narrowing in 44% of grafts by five years, especially in hyperlipidaemic Thompson patients. 26 The longest follow up to date has been reported by Campeau et al. 27 of 132 grafts shown to be patent at 6-18 months, 38% were unchanged at 10-12 years, 32% had changes suggestive of atherosclerosis ( Figure) , and 30%'/o had completely occluded.
The annual occlusion rate was 2-1% during the first five years and 5*2% thereafter. Concentrations of LDL cholesterol and LDL-apoB, the significance of which has been discussed recently,28 were higher and HDL cholesterol concentrations were lower in patients with graft atherosclerosis than in those without. 
